Cargando…
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
PURPOSE OF REVIEW: Etanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe. The recent patent expiration of the etanercept originator ENBREL in Europe has facilitated the development of biosimilar products, creating t...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244902/ https://www.ncbi.nlm.nih.gov/pubmed/30411183 http://dx.doi.org/10.1007/s11926-018-0799-0 |